PRLog - Apr. 4, 2012 - NEEDHAM, Mass. -- NEEDHAM, MASS. – Cambridge Healthtech Institute’s Insight Pharma Affiliated Reports Collection announces the Competitor Analysis: HIV Small Molecule Therapeutics Report, published by La Merie Business Intelligence.
This report used to treat human immunodeficiency virus (HIV) infections provides a competitor evaluation in the field of marketed products and R&D projects of HIV small molecule therapeutics as of December 2011.
The report includes a compilation of marketed products and currently active projects in research and development of HIV Small Molecule Therapeutics. In addition, the report lists company-specific product portfolios and R&D pipelines of HIV Small Molecule Therapeutics. Competitor projects are listed in a tabular format providing information on:
•Target / Mechanism of Action,
•Class of Compound,
•R&D Stage and
•additional comments with a hyperlink leading to the source of information.
For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/
# # #
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.